Novavax (NVAX)

Quick facts

Marketed products

• Licensed seasonal influenza vaccine · Immunology / Infectious Disease
  Novavax's seasonal influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.
• Pfizer mRNA COVID-19 vaccine
• protein subunit: Novavax COVID-19 vaccine · Immunology / Infectious Disease
  The Novavax COVID-19 vaccine delivers recombinant SARS-CoV-2 spike protein nanoparticles with an adjuvant to stimulate immune responses against the virus.

Phase 3 pipeline

• cTIV · Immunology / Infectious Disease
  cTIV is a recombinant tetravalent influenza vaccine designed to provide broader and more durable immune protection against multiple influenza virus strains.
• NanoFlu · Immunology / Infectious Disease
  NanoFlu is a recombinant nanoparticle-based influenza vaccine that displays hemagglutinin proteins on virus-like particles to stimulate robust immune responses.
• Novavax COVID-19 Vaccine · Immunology
  Novavax COVID-19 Vaccine uses recombinant spike protein nanoparticles with a saponin-based adjuvant to stimulate immune responses against SARS-CoV-2.
• NVX-CoV2373 + NVX-CoV2515 · Immunology / Infectious Disease
  A bivalent recombinant protein vaccine that stimulates immune responses against both the original SARS-CoV-2 strain and the Omicron variant to prevent COVID-19.
• NVX-CoV2373 + NVX-CoV2540 · Immunology / Infectious Disease
  A bivalent recombinant protein vaccine that elicits immune responses against both the original SARS-CoV-2 strain and the Omicron variant to prevent COVID-19.
• NVX-CoV2515 · Immunology / Infectious Disease
  NVX-CoV2515 is a recombinant protein subunit vaccine that presents the SARS-CoV-2 spike protein to stimulate immune responses against COVID-19 variants.
• NVX-CoV2540 · Immunology / Infectious Disease
  NVX-CoV2540 is a recombinant protein vaccine that presents the SARS-CoV-2 spike protein to stimulate immune responses against multiple variants of concern.
• NVX-CoV2705 Vaccine · Immunology / Infectious Disease
  NVX-CoV2705 is a recombinant protein subunit vaccine that presents SARS-CoV-2 spike protein antigens to stimulate adaptive immune responses against COVID-19 variants.
• RSV-F Vaccine · Immunology / Infectious Disease
  RSV-F Vaccine stimulates the immune system to produce antibodies and cellular immunity against the respiratory syncytial virus fusion (F) protein, preventing RSV infection.
• RSV F vaccine with adjuvant · Immunology / Infectious Disease
  This vaccine stimulates the immune system to produce antibodies and cellular immunity against the respiratory syncytial virus (RSV) F protein, preventing RSV infection.
• SARS-CoV-2 rS antigen/Matrix-M Adjuvant · Immunology / Infectious Disease
  This vaccine delivers the SARS-CoV-2 spike protein antigen with Matrix-M adjuvant to stimulate immune responses against COVID-19.
• SARS-CoV-2 rS/Matrix M1-Adjuvant · Infectious Disease
  SARS-CoV-2 rS/Matrix M1-Adjuvant is a vaccine that uses the SARS-CoV-2 spike protein and Matrix M1 adjuvant to stimulate an immune response against SARS-CoV-2.
• tNIV Vaccine

Phase 2 pipeline

• CIC Vaccine with Matrix-M Adjuvant · Immunology
  The CIC vaccine with Matrix-M adjuvant works by stimulating the body's immune system to produce a protective response against the COVID-19 virus.
• Dose 1 of Aluminum Adjuvant
• High dose RSV F Antigen
• High dose RSV-F Vaccine with Adjuvant
• High dose RSV-F Vaccine without Adjuvant
• Influenza VLP Vaccine
• Low dose RSV F Antigen
• Low dose RSV-F Vaccine with Adjuvant
• Low dose RSV-F Vaccine without Adjuvant
• Novavax Quadrivalent vaccine
• Novavax Trivalent vaccine
• qNIV Vaccine with Matrix-M Adjuvant

Phase 1 pipeline

• Adjuvant 1
• Base Dose EBOV GP Vaccine
• Fluzone HD - Day 0
• Fluzone HD - Day 21
• H5N1 VLP Vaccine
• ICC Vaccine
• Matrix-M Adjuvant
• RSV-F Particle Vaccine
• SARS-CoV-2 rS - Phase 1

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Novavax portfolio CI brief
• Novavax pipeline updates RSS